FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891755431> ?p ?o ?g. }

• W2891755431 abstract "e15054 Background: Molecular testing and location of the primary tumor (right-sided (R) versus (vs) left-sided (L)) are useful in predicting the clinical benefit of the anti-epidermal growth factor receptor (EGFR) antibodies, cetuximab (cet) and panitumumab (pan), in metastatic colorectal cancer (mCRC). We hypothesized that tumor bulk might also be predictive of treatment benefit given the potential for increased intra-tumor heterogeneity and reduced penetration of antibodies into bulkier lesions. Methods: A single institution retrospective cohort of 69 patients (pts) with KRAS wild-type mCRC were identified who received either cet or pan in the late-line setting +/- chemotherapy. Metastatic sites were cataloged including independent review of CT imaging prior to initiation of anti-EGFR therapy. Disease bulk was defined categorically as single metastatic lesion with diameter measuring > 3.0 cm. Results: This cohort represents a diverse group having received varying prior lines of therapy and having assorted disease sites including mediastinal, pulmonary, hepatic, omental, and osseous lesions. When treated with anti-EGFR therapies, pts with pre-treatment metastases ≤3.0 cm in diameter had significant improvement in median progression free survival (mPFS) (6.2 months (mos)) vs pts with metastases > 3.0 cm (3.9 mos, p < 0.01). A trend towards improvement in overall survival was observed for pts with non-bulky (15.8 mos) vs bulky disease (8.6 mos, p = 0.08). A trend towards increased mPFS existed in L (5.1 mos) vs R cancers (2.5 mos, p = 0.11). In R cancers, no significant difference in mPFS was noted between bulky (2.5 mos) and non-bulky disease (2.9 mos, p = 0.53). Non-bulky L cancers had a significantly improved mPFS of 7.5 mos compared to 3.9 mos with L bulky disease (p < 0.01). Non-bulky L cancers trended towards improved overall survival of 17.0 mos compared to 9.6 mos with L bulky disease (p = 0.08). Conclusions: Despite limited small sample size, these data indicate that tumor bulk is a potential predictor of the therapeutic benefit of anti-EGFR agents in left-sided mCRCs across a heterogeneous pt population. Disease bulk deserves further evaluation in larger datasets of mCRC across targeted therapeutics." @default.
• W2891755431 created "2018-09-27" @default.
• W2891755431 creator A5004212252 @default.
• W2891755431 creator A5004243407 @default.
• W2891755431 creator A5021338173 @default.
• W2891755431 creator A5022835462 @default.
• W2891755431 creator A5048019436 @default.
• W2891755431 creator A5048201634 @default.
• W2891755431 creator A5069462238 @default.
• W2891755431 creator A5073811035 @default.
• W2891755431 creator A5079022788 @default.
• W2891755431 creator A5087941123 @default.
• W2891755431 date "2017-05-20" @default.
• W2891755431 modified "2023-09-27" @default.
• W2891755431 title "Tumor bulk as an independent marker of anti-EGFR therapeutic benefit in metastatic colorectal cancer." @default.
• W2891755431 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.e15054" @default.
• W2891755431 hasPublicationYear "2017" @default.
• W2891755431 type Work @default.
• W2891755431 sameAs 2891755431 @default.
• W2891755431 citedByCount "0" @default.
• W2891755431 crossrefType "journal-article" @default.
• W2891755431 hasAuthorship W2891755431A5004212252 @default.
• W2891755431 hasAuthorship W2891755431A5004243407 @default.
• W2891755431 hasAuthorship W2891755431A5021338173 @default.
• W2891755431 hasAuthorship W2891755431A5022835462 @default.
• W2891755431 hasAuthorship W2891755431A5048019436 @default.
• W2891755431 hasAuthorship W2891755431A5048201634 @default.
• W2891755431 hasAuthorship W2891755431A5069462238 @default.
• W2891755431 hasAuthorship W2891755431A5073811035 @default.
• W2891755431 hasAuthorship W2891755431A5079022788 @default.
• W2891755431 hasAuthorship W2891755431A5087941123 @default.
• W2891755431 hasConcept C121608353 @default.
• W2891755431 hasConcept C126322002 @default.
• W2891755431 hasConcept C143998085 @default.
• W2891755431 hasConcept C2779998722 @default.
• W2891755431 hasConcept C502942594 @default.
• W2891755431 hasConcept C526805850 @default.
• W2891755431 hasConcept C71924100 @default.
• W2891755431 hasConceptScore W2891755431C121608353 @default.
• W2891755431 hasConceptScore W2891755431C126322002 @default.
• W2891755431 hasConceptScore W2891755431C143998085 @default.
• W2891755431 hasConceptScore W2891755431C2779998722 @default.
• W2891755431 hasConceptScore W2891755431C502942594 @default.
• W2891755431 hasConceptScore W2891755431C526805850 @default.
• W2891755431 hasConceptScore W2891755431C71924100 @default.
• W2891755431 hasLocation W28917554311 @default.
• W2891755431 hasOpenAccess W2891755431 @default.
• W2891755431 hasPrimaryLocation W28917554311 @default.
• W2891755431 hasRelatedWork W1963513036 @default.
• W2891755431 hasRelatedWork W1989409930 @default.
• W2891755431 hasRelatedWork W2035202434 @default.
• W2891755431 hasRelatedWork W2045102175 @default.
• W2891755431 hasRelatedWork W2058539457 @default.
• W2891755431 hasRelatedWork W2086127297 @default.
• W2891755431 hasRelatedWork W2147869500 @default.
• W2891755431 hasRelatedWork W2275818148 @default.
• W2891755431 hasRelatedWork W2373439286 @default.
• W2891755431 hasRelatedWork W2555386347 @default.
• W2891755431 hasRelatedWork W2587687460 @default.
• W2891755431 hasRelatedWork W2590421165 @default.
• W2891755431 hasRelatedWork W2618089978 @default.
• W2891755431 hasRelatedWork W2623055186 @default.
• W2891755431 hasRelatedWork W2907962653 @default.
• W2891755431 hasRelatedWork W2965261679 @default.
• W2891755431 hasRelatedWork W3010603582 @default.
• W2891755431 hasRelatedWork W3091309223 @default.
• W2891755431 hasRelatedWork W3125478083 @default.
• W2891755431 hasRelatedWork W3164366007 @default.
• W2891755431 isParatext "false" @default.
• W2891755431 isRetracted "false" @default.
• W2891755431 magId "2891755431" @default.
• W2891755431 workType "article" @default.